
MEDNAX (MD) Stock Forecast & Price Target
MEDNAX (MD) Analyst Ratings
Bulls say
Pediatrix Medical Group Inc has demonstrated a solid performance in its financial results, reporting a 4.0% year-over-year same-unit revenue increase, primarily driven by a 6.7% growth in net reimbursement-related factors. The company benefits from a favorable reimbursement environment, which is further supported by improved birth rates, contractual wins with hospitals, and a favorable commercial payor mix, positioning it for continued revenue growth. Additionally, the strong balance sheet of Pediatrix enhances its financial stability and provides a foundation for potential strategic investments and capital deployment, contributing to a positive long-term outlook.
Bears say
Pediatrix Medical Group Inc reported total revenue of $493.8 million, which was slightly below expectations despite a year-over-year same-unit revenue growth of 6.7%, indicating potential challenges in patient volume with a decrease of 2.7%. The company is encountering downside risks such as sluggish same-unit trends, increased competition for mergers and acquisitions, a decline in birth rates, and heightened reimbursement risks that could adversely affect its financial stability. Additionally, adjusted EBITDA estimates remain unchanged for 2026 and 2027, but the lowered revenue forecasts reflect a concerning outlook for sustained growth, suggesting a need for strategic adjustments to navigate competitive pressures and health care market dynamics.
This aggregate rating is based on analysts' research of MEDNAX and is not a guaranteed prediction by Public.com or investment advice.
MEDNAX (MD) Analyst Forecast & Price Prediction
Start investing in MEDNAX (MD)
Order type
Buy in
Order amount
Est. shares
0 shares